SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 01, 2008) - Pharmaceutical company Novogen Limited (NASDAQ: NVGN) (ASX: NRT) today announced that work performed in collaboration with a Yale University research team led by Associate Professor Gil Mor, MD, PhD, has revealed its novel mTOR inhibitor NV-128 has the potential to act against cancer stem cells in addition to rapidly proliferating cells in established solid tumors.
